including AR, PTEN, and p53 status. BL140 was superior than GSK2636771 (IC 50 5.74 vs 20.49 nM), the only p110β-selective inhibitor currently in clinical trials, as revealed in an in vitro Kinase-Glo assay. Furthermore, BL140 exhibited a stronger inhibitory effect than GSK2636771 on multiple CRPC cell lines including a MDV3100-resistant C4-2B cell subline, indicating BL140 elimination of MDV3100 resistance. Mechanistic studies revealed that BL140 blocked G 1 phase cell cycle entry by reducing cyclin D1 but increasing p27 kip1 protein levels.
Conclusion: These studies suggested that BL140 is a promising p110β-specific inhibitor with multiple superb properties than GSK2636771 worthy for further clinical development.
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| INTRODUCTION
Prostate cancers in the castration-resistant stage (CRPC) are lifethreatening as they are not curable in clinic. 1 Despite the development of novel androgen receptor antagonist CYP17 inhibitor Abiraterone, Enzalutamide, or new immunotherapies, patient survival was only
prolonged for a few months in advanced prostate cancers. [2] [3] [4] Therefore, novel therapy is urgently needed for advanced prostate cancers.
Phosphatidylinositol 3-kinases (PI3Ks) are major cellular signaling molecules that regulate multiple cellular functions. 5 The class I PI3Ks have two subtypes, IA p110α/β/δ and IB p110γ. PI3K class IA p110α and p110β are ubiquitously expressed, but there is a functional diversity between these two isoforms. 6 The p110β has a distinct role different from p110α in cell survival, DNA replication, cell mitosis, and male fertility while the p110α is mostly associated with insulin or growth factor pathways. 7, 8 Due to the inactivating mutation of PI3K negative regulator PTEN gene (phosphatase and tensin homologue deleted on chromosome 10) or gain-of-function mutations on PI3K
isoform genes, elevated PI3K activity has been proposed as one of the major mechanisms for many types of human cancers including prostate cancers. 9, 10 Meanwhile, recent genomic analysis and deep sequencing data revealed that genetic abnormalities in PTEN/PI3K-AKT were found in up to 40-70% of patients. 5, 11 Most interestingly, a novel fusion gene with an androgen-regulated prostate-specific acid phosphatase (ACPP) at the 5′ (exon 1-2) fused to PIK3CB gene was found in a castration-resistant prostate cancer patient, 12 representing one potential mechanism of PIK3CB gene upregulation as reported in our publication. 13 In addition, current anti-androgen therapies were found to cause elevated PI3K/AKT activation due to compensatory mechanism, indicating combinational inhibition of both PI3K/AKT pathway and androgen receptor has much more advantage compared to single therapy. [14] [15] [16] [17] [18] In our previous studies, we demonstrated that the PIK3CB gene is highly expressed in patient cancer specimens and the p110β protein activity plays a critical role during prostate cancer progression as determined in cell culture and nude mouse xenograft models. 13 Our data were supported by other groups using PTEN/ PIK3CB knockout mouse models, as well as cell biology and biochemical experiments. [19] [20] [21] [22] In the era of precise medicine, we sought to develop novel targeted therapy for prostate cancer. The very first p110β isoformspecific inhibitor TGX221 was developed in 2005 23 based on the structure of a pan-PI3K reversible inhibitor LY294002, which was derived from a natural bio-flavinoid Quercetin. 24 In the past few years, we demonstrated that TGX221, either in naked or pro-drug format, inhibited prostate cancer cell proliferation in vitro and blocked prostate cancer xenograft tumor growth in vivo. [25] [26] [27] However, TGX221 is not water soluble, representing a huge obstacle for further clinical development. To bypass this roadblock,
we recently redesigned and synthesized multiple TGX221 analogs 28 attempted to improve its aqueous solubility while retain its inhibitory effect toward PI3K/p110β. In this study, we tested these TGX221
analogs regarding their aqueous solubility, target engagement, and inhibitory effect on PI3K/p110β activity. Our data showed that these TGX221 analogs exerted distinct inhibitory effect on AKT 
| Cellular thermal shift assay
Target engagement of the analogs with PI3K isoform proteins was examined with CETSA assay as described recently. 31 Signal intensity of Western blot bands were quantified individually using Image J software. Data were normalized by setting the highest and lowest value in each set to 100% and 0%, respectively. The relative signal intensities were plotted against temperature (melting curves) and fitted by applying Boltzmann Sigmoid at least squares using the Graphpad Prism 5.0 software (La Jolla, CA). Thermal shifts were compared using ΔT m 50 values that were calculated as temperature differences between compound and solvent treatments at a 50% reduction of band density.
| Western blot and Kinase-Glo in vitro kinase assays
After treatment, cellular protein lysates were prepared in RIPA buffer (Cell Signaling) supplemented with a complete protease inhibitor cocktail. Equal amount of proteins from each lysate was subjected to SDS-PAGE gels, electrophoresed, and transferred onto PVDF membrane. The membrane was incubated with primary antibody overnight at 4°C after blocking with 10% nonfat dried milk for 1 h.
Membranes were then incubated with horseradish peroxidaseconjugated secondary antibody and immunosignal was developed in a chemiluminescent reagent (Santa Cruz Biotech). Actin blot was used as an internal protein loading control in all blotting membranes.
PI3K activity assays were carried out using the Kinase-Glo Plus 3 | RESULTS
| Flow cytometry and cell growth inhibition assay

| TGX221 analogs exerts a high solubility in aqueous solution
TGX221 has been used as an anti-thrombotic and anti-tumor agent in vitro and in vivo. [25] [26] [27] However, the clinical development of TGX221
as an anti-cancer drug was hampered due to its poor water solubility (<1.0 mg/mL). To overcome this obstacle, we redesigned and synthesized multiple TGX221 analogs, 28 as illustrated in Fig. 1 . As expected, replacing either one of two major functional groups circled in red or blue dashed lines in TGX221 by more hydrophilic groups, their aqueous solubility was dramatically improved compared to TGX221
(about 40-fold increase, Table 1 ). It was also over 70-fold higher compared to the compound SAR260301 (0.928 mM) 32 ,33 that was recently tested in clinical trial (NCT01673737). These promising data encouraged us to conduct a detailed characterization of these analogs in prostate cancer cells.
| TGX221 analogs exert a high specificity of target engagement
We first utilized the cellular thermal shift assay (CETSA) 34 to determine the engagement of TGX221 analogs with the target protein p110β, as well as other PI3K isoforms if any. To eliminate potential interplays among cellular proteins in living cells, we used PC-3 cellular protein lysates for these CETSA assays according to the published protocol. 31 Our data revealed that TGX221 and its four analogs dramatically altered p110β thermos-melting curve comparing to the solvent control (Fig. 2B ). In contrast, none of them largely shifted the thermo-melting curves of other class I PI3K proteins p110α ( Fig. 2A ) and p110γ
( Fig. 2C) , as well as their major downstream target Akt protein (Fig. 2E ), although the compound BL147 moderately changed the melting curve of class III PI3K VPS34 protein (Fig. 2D ).
Then, we verified the p110β engagement properties of the TGX221 analogs in living cells. Exponentially grown PC-3 cells were treated with these compounds for 2 h and harvested for the CETSA assays. Similar as the in vitro CETSA assay data, these analogs strongly altered the thermo-melting curve of p110β protein (Fig. 2F) but not Akt protein (Fig. 2G ). The ΔT m 50 values for all analogs were summarized in Table 2 . These data suggest that these TGX221 analogs are specifically engaged with PI3K class IA p110β protein except BL147 also for VPS34.
FIGURE 1
Chemical structure of TGX221 and its analogs. Two major functional groups were circled in red or blue dashed lines FIGURE 2 TGX221 and its analogs are specifically engaged with PI3K p110β protein. Cellular protein lysates from exponentially grown PC-3 cells were mixed with the solvent DMSO or the compounds at 5 μM for 30 min followed by CETSA assay as described. 31 Panel A-E are from cell lysate CETSA and panel F-H are for whole cell CETSA. The signal intensity of bands was quantified using Image J. Data were then normalized by setting the highest and lowest value in each set to 100% and 0%, respectively. The relative signal intensities (protein melting curves) were plotted against temperatures using GraphPad Prism 5.0 and then were fitted by applying Boltzmann Sigmoid. The error bar represents SEM of the mean from three experiments (Fig. 3E) . These data strongly indicate that the BL140 analog is the best candidate of PI3K/p110β-specific inhibitor among these TGX221 analogs.
| BL140 possesses a highly p110β specificity
We next examined the BL140 specificity towards p110β with two different approaches. First, BL140's specificity and efficiency was tested in an in vitro Kinase-Glo luminescent kinase assay coupled with purified FIGURE 4 PI3K isoform specificity. Kinase-Glo in vitro kinase assays were carried out in a 20 μL kinase buffer system (4 mM DTT, 2 μM ATP, 5 mM PIP2:PS) containing active complex of p110α/p85α (0.05 μg), p110β/p85α (0.3 μg), or p110δ/p85α (0.1 μg) in the presence of the compound as indicated. Inhibition of individual kinase activity was calculated as a percentage reduction of luminescent signal in the presence of the compound compared to the solvent control (set as 100%). Data were plotted against the compound concentrations and curve fit was conducted using sigmoidal dose-response with variable slope (GraphPad Prism 5.0 software). Data were presented as MEAN ± SEM from three independent experiments. The parental LNCaP (D) and its PIK3CB silenced subline LNCaP/shPIK3CB#3 (E) were seeded in regular media and treated with the solvent or the compounds as indicated at 5 μM for 4 h. Cells were harvested and cellular protein lysates were subjected to Western blot with the antibodies as listed on the left side of each panel. F: The relative band density of pAkt S473 after normalized against total AKT compared to the DMSO control (set as 100%) was summarized and graphed. Data are representative of three separate experiments HE ET AL.
| 1193 recombinant class IA PI3K/p110x-p85α active protein mixture. Two previously reported PI3K inhibitors, BYL719 for p110α 35 and GSK2636771 for p110β, 36 were used as the isoform specificity control.
As expected, BYL719 showed a very specific effect on p110α activity (Fig. 4A ) and GSK2636771 on p110β (Fig. 4B) . However, GSK2636771 also exerted inhibitory effect on p110δ ( Fig. 4C and Table 3 ).
Interestingly, BL140 showed a very high specificity on p110β, similar as its predecessor TGX221 but a sharply weak inhibitory effect on p110α (150-fold weaker) or p110δ (745-fold weaker). The IC 50 values for all these compounds were summarized in Table 3 .
The second approach to test BL140 specificity on p110β was conducted on LNCaP and its subline LNCaP/shPIK3CB#3, which was established in our previous work by stably transfecting with a PIK3CB gene small-hairpin interfering RNA construct. 13 We reasoned that in a p110β-less cell, a given p110β-specific inhibitor will show a very limited inhibitory effect on Akt S473 phosphorylation since the target is missing. (Table 4) . For all cell lines tested, BL140 showed a similar efficiency as TGX221 but a much better performance than GSK2636771.
We also analyzed cell cycle phase distribution in C4-2B and its (Fig. 5G-H) . These data suggest that G 0 /G 1 arrest is responsible for these p110β-specific inhibitors-induced cell growth suppression.
We then compared the Akt pS473 status between these pair of C4-2B cells in response to BL140 and GSK2636771 treatment. C4-2B
and its MDV-R subline cells were serum-starved overnight and then pre-treated with the compounds followed by addition of 10% FBS. As shown in Fig. 6A , FBS-stimulated Akt pS473 levels in C4-2B cells were abolished by BL140 or GSK2636771 treatment but were enhanced by MDV3100 treatment, which was supported by previous reports that Akt activity was increased by AR antagonist. 14, 16 In MDV-R cells, BL140 abolished FBS-stimulated Akt pS473, however, GSK2636771
only partially suppressed FBS-stimulated Akt pS473 phosphorylation (Fig. 6B ). These data indicate that BL140 is superior on PI3K/AKT inhibition than GSK2636771 in MDV3100-resistant cells.
To understand the mechanism for G 1 /G 0 phase arrest, we analyzed the protein levels of three major factors for G 1 phase progression, cyclin D1, CDK6 and p27 kip1 . In both MDV3100-sensitive and -resistant C4-2B cell lines, cyclin D1 protein levels in control treatment were gradually increased with time after FBS addition, a sign of G 1 phase progression. Interestingly, this increase was largely suppressed by BL140 or GSK2636771 treatment, indicating a potential association of cyclin D1 reduction in G 1 phase arrest induced by BL140 and GSK2636771. Meanwhile, p27 kip1 protein levels were largely elevated in BL140-or GSK2636771-treated C4-2B cells but not in C4-2B/MDV-R cells. There was no obvious alteration of CDK6
protein levels between the control and compound treatments in MDV3100-sensitive or MDV3100-resistant C4-2B cells. These data suggest that p110β inhibition with BL140 or GSK2636771 eliminates MDV3100 resistance in castration-resistant prostate cancer cells by blocking cell cycle progression through cyclin D1 protein reduction.
Further in vivo testing in animal models are underway by our group.
| DISCUSSION
In this study, we characterized four novel TGX221 analogs (BL139, BL140, BL141, and BL147) for their aqueous solubility, target FIGURE 6 PI3K/p110β inhibition reduces cyclin D1 but increases p27 kip1 protein levels. C4-2B (A) and C4-2B/MDV-R (B) cells were serum-starved for overnight. After a 30-min pretreatment with the solvent or the compounds (5 μM), cells were stimulated with 10% FBS and harvested at different time-points as indicated for Western blot with the antibodies listed on the left side of each panel. Actin blots served as protein loading control. Data were representative of two separate experiments therapeutics. 38 As the very first PI3K/p110β-specific inhibitor, TGX221 has been used as an anti-thrombotic and anti-tumor agent in vitro and in vivo. [39] [40] [41] [42] Works from our group with TGX221-loaded prostate-cancer cell-homing nano-micelles documented the growth blockage of mouse orthotopic xenograft tumors derived from advanced prostate cancer cells, 25, 26 confirming the feasibility of p110β-targeted therapy for prostate cancer intervention. Although multiple p110β-specific inhibitors were reported, 43, 44 only GSK2636771 proceeded to phase-2 clinical trial (NCT01458067) for PTEN-negative solid tumors and another phase-1 trial is ongoing to test the combinational treatment of GSK2636771 plus MDV3100 in metastatic CRPC patients (NCT02215096). Another PI3K/p110β-specific inhibitor SAR260301 was failed in phase-1 trial (NCT01673737) due to rapid clearance from the system. 45 In this study, we demonstrated that the novel TGX221 analog BL140 possesses multiple favorable properties for clinical development as an anti-cancer therapy for PTEN-negative or p110β-prone cancers.
Our unpublished preliminary data also indicated that BL140 was very stable even in acidic solution that mimics human gastric secretion, suggesting a potential and convenient oral route for drug delivery.
MDV3100, also termed as Enzalutamide, is the latest AR antagonist in clinic, unfortunately, drug resistance has already become a critical issue in CRPC patients. Although the mechanisms underlying MDV3100 resistance remains incomplete known, the existence of AR variants that lack ligand binding domain has been pointed as the major cause. [46] [47] [48] In this study, we demonstrated that BL140 treatment resulted in G 1 phase arrest and cyclin D1 protein reduction not only in MDV3100-sensitive but also in MDV3100-resistant aggressive CRPC C4-2B cells. PTEN/ PI3K-Akt pathway has been shown as the major cellular pathway in regulating cell cycle entry and cyclin D1 protein levels possibly through GSK-3 dependent proteolysis. 49, 50 Disturbing this pathway, for example, PI3K inhibition, would result in cyclin D1 depletion and cell cycle arrest. 51 In addition, AR antagonist treatment was shown to enhance PI3K/AKT activity, 14, 16 therefore, blocking PI3K/p110β-Akt activation with BL140 could be used as a potential MDV3100 sensitizing agent for CRPCs as recently reported with Akt-specific inhibitor AZD5363. 52, 53 In conclusion, we characterized a group of novel TGX21 analogs with greatly improved aqueous solubility compared to the parent compound. One of the analogs BL140 possesses a consistent inhibitory effect on PI3K/AKT activity in multiple prostate cancer cell lines with diverse genetic background. BL140 is superior than GSK2636771 either in kinase inhibition or in cell growth suppression.
BL140 suppressed cell growth and blocks cell cycle entry not only in MDV3100-sensitive but also in MDV3100-ressistant C4-2B cells by reducing cyclin D1 protein levels. These data strongly indicate that BL140 is a promising candidate for further clinical development as a combined therapy with MDV3100 for CRPC patients. 
ACKNOWLEDGMENTS
DISCLOSURE STATEMENT
None.
